Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Bai, Y., Pan, Y
Clin Endocrinol (Oxf) (1986) 25:13342
Molecular Identity Developer Eli Lilly Brand Names Mounjaro (diabetes), Zepbound (obesity) Mechanism Dual GLP-1 and GIP receptor agonist FDA Status Approved (2022 diabetes, 2023 obesity) Administration Weekly subcutaneous GIP Receptor Pathway The GIP receptor activation in Tirzepatide provides different metabolic effects than glucagon: Incretin enhancement: GIP augments GLP-1's insulin-related signaling Adipose tissue effects: GIP receptor expression in fat tissue documented Tolerability profile: Some research suggests GIP may moderate GI effects Synergistic incretin signaling: Two incretin pathways vs
is the most-cited primary reference
Meibohm, B., & Derendorf, H
Read More Safety Information/Precaution Consult a healthcare professional before use, especially if pregnant, nursing, or have any existing medical conditions
US$ 28.85
US$ 26.39
US$ 21.77
US$ 24.62
